EXPERT-C Trial - Dr. Francesco Sclafani - 100351


EXPERT-C Trial - Dr. Francesco Sclafani

Description: For more updates visit

Dr. Francesco Sclafani with an update on ECC 2013 Abstract #2168. Neoadjuvant chemotherapy before standard CRT was associated with promising long-term outcomes in high-risk rectal cancer patients. Based on the absence of improvement in any of the study endpoints, cetuximab did not appear to be the optimal companion targeted agent to further increase the efficacy of this strategy. pCR was demonstrated to be a reliable surrogate end point for rectal cancer trials even in the context of intensified pre-operative regimens including induction chemotherapy.
Shared By : oncologyeducation
Posted on : 10/07/13
Added : 6 years ago
Category : Other